GSK (LSE:GSK) Gets Extended Gates Funding For Tuberculosis Drug Research

• GSK (LSE:GSK) and AN2 Therapeutics have secured extended funding for their tuberculosis research partnership from the Gates Foundation.
• The renewed backing supports work on boron-based LeuRS inhibitors, a new class of potential treatments targeting tuberculosis.
• The collaboration focuses on drug discovery that could affect future options for managing a major global infectious disease burden.
• The fresh Gates Foundation funding for boron-based LeuRS inhibitors is only one part of the wider GSK investment story. We have also spotted 3 warning signs worth knowing about at GSK.

GSK is not the only business exposed to the push for data driven drug discovery, so it is worth scanning peers through 8 healthcare AI stocks.

GSK, a £73.4b pharmaceuticals group that develops and manufactures vaccines and medicines across major global markets, uses partnerships such as this one with AN2 Therapeutics to extend its research reach into infectious diseases such as tuberculosis.

4 things going right for GSK that this headline doesn't cover.

Gates funding leans into GSK’s infectious disease R&D bull case

This fresh Gates Foundation backing reinforces the part of the GSK narrative that focuses on reinvestment in research and partnerships to support its long term story. Continued work on boron based LeuRS inhibitors fits the theme of GSK using collaborations to broaden its pipeline beyond oncology into infectious disease, which relates to the catalyst around accelerated R&D and business development. For investors, it supports the idea that external funders still see value in GSK’s discovery engine, even as the group manages legal outflows and the risk that some high cost programs may not translate into large commercial products.

See how these catalysts shape GSK's path to a £21.61 fair value.

The test for this development will come when GSK or AN2 discloses the next material clinical milestone for a LeuRS tuberculosis asset, for example a clear update on advancing a candidate into or through Phase 2. That would show whether this collaboration is progressing in line with the broader R&D led bull case.

One unresolved question for GSK sits in the boardroom

All of this still leaves one crucial thread untouched: which people sit at the top of GSK and what they are actually rewarded for delivering. See who is actually steering GSK, and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com